As a leader in pharmacogenomics (PGx), Admera offers the most comprehensive clinical PGx test in the industry, covering 62 genes, over 270 medications, and over 20 therapeutic areas.
September 28, 2021 09:00 AM Eastern Daylight Time
SOUTH PLAINFIELD, N.J.–(BUSINESS WIRE)–Admera Health, a precision-medicine company and genetics laboratory, announced today that it has engaged Back Bay Life Science Advisors, a strategic advisory and investment banking firm, to explore strategic alternatives for its pharmacogenomics and clinical services business as part of a company-wide strategic review. Admera offers the most comprehensive clinical PGx test in the industry, covering 62 genes, over 270 medications, and over 20 therapeutic areas, including: psychiatry, cardiology, pain management, and oncology. Admera Health’s clinical services portfolio is built on a strong foundation of next-generation sequencing (NGS) and data analysis capabilities.
The company’s current PGx and clinical services product portfolio consists of:
- PGxOne™ Plus is a 62-gene pharmacogenomics test that provides insight into how patients may respond to certain medications based on DNA variants that affect pharmacokinetics and pharmacodynamics
- RxVision™ is a secure, online digital platform that delivers PGx test results to providers and offers a complete PGx assessment with the gene-drug interactions aligning with the FDA sources and guidelines from professional organizations. The product is accessible on web-based browsers, as well as iOS and Android mobile devices, obviating the need for complicated integration with electronic medical record systems
- OncoGxOne™ is a comprehensive 364-gene Next Generation Sequencing assay for profiling all solid tumor types. Input includes both DNA and RNA for optimal fusion detection. The product compliments Admera Health’s suite of NGS tests, spanning the continuum of cancer patient care
The company has also capitalized on its infrastructure by partnering with other domain experts to expand its product offering, notably with its Cardiovascular Test Portfolio.
“We are proud of the significant commercial value we have built in our pharmacogenomics products and are looking to select a strategic partner with additional scale and resources to realize their full potential,” said Jeffrey Mitchell, interim CEO of Admera Health.
The company will continue to own and operate its biopharma services business, providing genomics and bioinformatics services in a CAP-accredited CLIA certified laboratory for researchers working on projects ranging from exploratory to clinical.
About Admera Health
Admera Health is a CLIA Certified/CAP Accredited laboratory, providing a suite of high-integrity pharmacogenomics solutions, diagnostic testing, and biopharmaceutical research services headquartered in South Plainfield, New Jersey.
About Back Bay Life Science Advisors
Back Bay Life Science Advisors provides life science strategy and investment banking to the global life science industry, including pharma, biotech, medtech, academia, and investors.
Back Bay works with companies of all sizes across the US and global life science markets, across every stage, sector, geography, and therapeutic area. Back Bay strategy and banking teams guide companies on technology and drug development, from planning and initial concept to product commercialization, franchising and licensing, M&A, divestiture, and more.
With headquarters in Boston’s Back Bay neighborhood, Back Bay teams are staffed with MDs, PhDs, science and banking experts with proven knowledge and love for new technologies, medicines, and scientific approaches.
Learn more about Back Bay Life Science Advisors and subscribe for life science industry updates at www.bblsa.com.
For More Information
Back Bay Life Science Advisors is acting as the exclusive strategic and financial advisor to Admera Health. For more information, interested parties are asked to contact Christina Vorvis, Ph.D. (email@example.com).
Back Bay Life Science Advisors